<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719108</url>
  </required_header>
  <id_info>
    <org_study_id>WosulinR/PK-PD/HV/EMEA/2008/v2</org_study_id>
    <nct_id>NCT00719108</nct_id>
  </id_info>
  <brief_title>Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.</brief_title>
  <official_title>Randomized,Single Center,Double Blind,Two-period,Crossover Glucose Clamp Trial to Test Bioequivalence Between Two Recombinant Human Soluble Insulins - Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to demonstrate bioequivalence of Wosulin R to Actrapid with regard&#xD;
      to its total and to its maximum serum insulin concentrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is the comparative evaluation of the Pharmacodynamics and&#xD;
      Pharmacokinetics of two recombinant regular human insulin injections administered&#xD;
      intravenously in healthy volunteers under the conditions of euglycemic clamp.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the GIR-time curve at steady state from 240 to 300 minutes (AUCGIR-SS)</measure>
    <time_frame>Visit 2 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints: Area under the GIR-time curve from 0 to 7 hours, GlR at steady state. PK Endpoints: AUCINS-SS, AUCINS0-7h, CLtot, VSS, t1/2 ,Terminal rate constant Safety Endpoints: AE, Lab assessments, Vital signs, Phy Exam, ECG &amp; Hypoglycemia.</measure>
    <time_frame>Visit 2 , 3 and 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Wosulin R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Actrapid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Wosulin R</intervention_name>
    <description>Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.</description>
    <arm_group_label>Wosulin R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Actrapid</intervention_name>
    <description>Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.</description>
    <arm_group_label>Actrapid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female subject&#xD;
&#xD;
          2. Age between 18 and 45 years (both inclusive)&#xD;
&#xD;
          3. Considered generally healthy upon completion of medical history, physical examination&#xD;
             and biochemical investigations as judged by the Investigator.&#xD;
&#xD;
          4. Body Mass Index (BMI) between 18.0 and 35.0 kg/m2 (both inclusive)&#xD;
&#xD;
          5. Non-smoker, defined as no nicotine consumption for at least one year.&#xD;
&#xD;
          6. Signed and dated informed consent obtained before any trial-related activities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous participation in this trial or other clinical trials within the last 3&#xD;
             months.&#xD;
&#xD;
          2. Pregnant, breast-feeding or intention of becoming pregnant or not using adequate&#xD;
             contraceptive measures.&#xD;
&#xD;
          3. Clinically significant abnormal hematology or biochemistry screening tests, as judged&#xD;
             by the Investigator.&#xD;
&#xD;
          4. Any serious systemic infectious disease during the four weeks prior to the first dose&#xD;
             of test drug, as judged by the Investigator.&#xD;
&#xD;
          5. History of any illness that, in the opinion of the Investigator, might confound the&#xD;
             results of the trial or pose risk in administering the trial drug to the subject. In&#xD;
             particular, subjects with significant cardiovascular disease, anemia (below the lower&#xD;
             limit of normal) or hemoglobinopathy will not be allowed to enter the trial.&#xD;
&#xD;
          6. History of alcohol or drug abuse within the past 5 years and/or any positive test for&#xD;
             drugs of abuse at screening.&#xD;
&#xD;
          7. Positive test for hepatitis B or C or HIV positive at screening or in the past.&#xD;
&#xD;
          8. Use of prescription drugs within 3 weeks preceding the first dosing of insulin, except&#xD;
             for oral contraceptives/hormonal implants.&#xD;
&#xD;
          9. Use of any insulin product in the past.&#xD;
&#xD;
         10. Use of non-prescription drugs, except routine vitamins, within 2 weeks prior to the&#xD;
             first dose of the test drug. Occasional use of acetaminophen will be permitted.&#xD;
&#xD;
         11. Blood donation of more than 500 mL (or considerable blood loss) within the last 12&#xD;
             weeks.&#xD;
&#xD;
         12. History of multiple and/or severe allergies to drugs or foods or a history of severe&#xD;
             anaphylactic reaction.&#xD;
&#xD;
         13. Known or suspected allergy to trial products or related products.&#xD;
&#xD;
         14. Mental incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or co-operation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Hompesch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Profil Institute of Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>July 18, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <last_update_submitted>December 26, 2012</last_update_submitted>
  <last_update_submitted_qc>December 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes, Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

